source
- Evaxion Biotech Shifts R&D Focus Exclusively to Cancer Vaccines, Halts Infectious and Autoimmune ProgramsEvaxion Biotech announced it is ending its infectious disease and autoimmune research programs to concentrate solely on oncology. The company’s most advanced candidate is EVX-01, a therapeutic can…
- CLINUVEL to cut up to 20% of staff and move headquarters to New YorkCLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…